A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease

Exclusion Criteria

• •Any significant neurologic disease other than AD
• •History of Diabetes Mellitus type I or II
• •Any contraindications to MRI or PET studies
• •Major depression, bipolar disorder as described within the past 1 year.
• •History of schizophrenia
• •History of alcohol or substance abuse or dependence within the past 2 years
• •Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol
• •Current use of specific psychoactive medications
• •Investigational amyloid lowering therapies are prohibited two months prior to screening and for the duration of the trial. Other investigational agents are prohibited one month prior to screening and for the duration of the trial.
• •History of brain cancer
• •1. Any significant neurologic disease other than FTD, such as Alzheimer disease, progressive supranuclear palsy, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, space occupying brain lesion, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
• •2. History of Diabetes Mellitus type I or II; Hb A1C \> 6.0
• •3. Subjects that have any contraindications to MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, cardiac pacemaker will be excluded from the study, or known bleeding disorder.
• •4. Major depression, bipolar disorder, or schizophrenia as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol.
• •5. Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol.
• •6. Current use (sporadic or chronic, within 30 days of screening) of specific psychoactive medications (e.g. typical neuroleptics, narcotic analgesics, anti-Parkinsonian medications, systemic corticosteroids, or medications with significant central anticholinergic activity, etc.)
• •7. Current use of warfarin or other anti-coagulants.
• •8. Current or recent participation in any procedures involving radioactive agents, including current, past, or anticipated exposure to radiation in the workplace, such that the total radiation dose exposure to the subject in a given year would exceed the limits of annual and total dose commitment set forth in the Health Canada guidelines
• •9. AST, ALT, total bilirubin \>1.5 times the upper limit of normal;
• •10. Serum creatinine \>1.5 times the upper limit of normal
• •11. Has a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators.
• •12. Regular use of MCT products within 30 days of screening. (eg coconut oil, palm oil, coconut milk)
• •13. History of brain cancer